CN101302537A - 一种位点特异整合性慢病毒载体系统及其制备方法 - Google Patents
一种位点特异整合性慢病毒载体系统及其制备方法 Download PDFInfo
- Publication number
- CN101302537A CN101302537A CNA2008100374409A CN200810037440A CN101302537A CN 101302537 A CN101302537 A CN 101302537A CN A2008100374409 A CNA2008100374409 A CN A2008100374409A CN 200810037440 A CN200810037440 A CN 200810037440A CN 101302537 A CN101302537 A CN 101302537A
- Authority
- CN
- China
- Prior art keywords
- plasmid
- site
- preparation
- cmv
- slow virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title claims abstract description 33
- 230000010354 integration Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 22
- 230000001177 retroviral effect Effects 0.000 title claims description 17
- 239000013612 plasmid Substances 0.000 claims abstract description 45
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims abstract description 3
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102200017779 rs10132601 Human genes 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 108700004029 pol Genes Proteins 0.000 claims description 6
- 101150088264 pol gene Proteins 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 108010002459 HIV Integrase Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 108010061833 Integrases Proteins 0.000 abstract description 6
- 238000001415 gene therapy Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 108700019146 Transgenes Proteins 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract description 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 102400000584 C31 Human genes 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 3
- 206010041047 Slow virus infection Diseases 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001483952 Peach chlorotic mottle virus Species 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000013326 plasmid cotransfection Methods 0.000 description 1
- 101150027686 psaF gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102200071927 rs667782 Human genes 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100374409A CN101302537B (zh) | 2008-05-15 | 2008-05-15 | 一种位点特异整合性慢病毒载体系统及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100374409A CN101302537B (zh) | 2008-05-15 | 2008-05-15 | 一种位点特异整合性慢病毒载体系统及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101302537A true CN101302537A (zh) | 2008-11-12 |
CN101302537B CN101302537B (zh) | 2010-09-15 |
Family
ID=40112638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100374409A Expired - Fee Related CN101302537B (zh) | 2008-05-15 | 2008-05-15 | 一种位点特异整合性慢病毒载体系统及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101302537B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102851317A (zh) * | 2011-06-30 | 2013-01-02 | 复旦大学 | 用于艾滋病基因治疗的携带多靶点RNAi的慢病毒制备及应用 |
CN103232977A (zh) * | 2013-05-16 | 2013-08-07 | 西南大学 | phiC31重组酶系统和piggyBac转座子的应用及其家蚕定点转基因系统和制备方法 |
CN104926944A (zh) * | 2015-05-22 | 2015-09-23 | 北京康爱瑞浩生物科技股份有限公司空港分公司 | 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途 |
CN105238818A (zh) * | 2015-09-29 | 2016-01-13 | 潘雨堃 | 一种在体内精原干细胞基因组中引入随机插入突变的方法 |
CN105331636A (zh) * | 2015-12-04 | 2016-02-17 | 广州伯尼兹生物科技有限公司 | 一种稳定表达猪瘟病毒e2蛋白的重组细胞系及其应用 |
CN106399376A (zh) * | 2016-08-31 | 2017-02-15 | 河南省华隆生物技术有限公司 | 一种整合缺陷型慢病毒载体、其制备方法及应用 |
-
2008
- 2008-05-15 CN CN2008100374409A patent/CN101302537B/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102851317A (zh) * | 2011-06-30 | 2013-01-02 | 复旦大学 | 用于艾滋病基因治疗的携带多靶点RNAi的慢病毒制备及应用 |
CN103232977A (zh) * | 2013-05-16 | 2013-08-07 | 西南大学 | phiC31重组酶系统和piggyBac转座子的应用及其家蚕定点转基因系统和制备方法 |
CN104926944A (zh) * | 2015-05-22 | 2015-09-23 | 北京康爱瑞浩生物科技股份有限公司空港分公司 | 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途 |
CN105238818A (zh) * | 2015-09-29 | 2016-01-13 | 潘雨堃 | 一种在体内精原干细胞基因组中引入随机插入突变的方法 |
CN105331636A (zh) * | 2015-12-04 | 2016-02-17 | 广州伯尼兹生物科技有限公司 | 一种稳定表达猪瘟病毒e2蛋白的重组细胞系及其应用 |
CN106399376A (zh) * | 2016-08-31 | 2017-02-15 | 河南省华隆生物技术有限公司 | 一种整合缺陷型慢病毒载体、其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101302537B (zh) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210401868A1 (en) | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules | |
Sauter et al. | Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains | |
CN101302537B (zh) | 一种位点特异整合性慢病毒载体系统及其制备方法 | |
EP4036223A1 (en) | Lentiviral delivery of cas constructs for the treatment and prevention of hiv-1 infections | |
Hu et al. | Homologous recombination occurs in a distinct retroviral subpopulation and exhibits high negative interference | |
JP4482578B2 (ja) | 真核細胞にヌクレオチド配列を挿入し得る天然または合成のレトロエレメント配列 | |
CN101287834A (zh) | 基因载体 | |
WO1993011230A1 (en) | Modified mammalian stem cell blocking viral replication | |
Corbeau et al. | Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system | |
St. Louis et al. | Infectious molecular clones with the nonhomologous dimer initiation sequences found in different subtypes of human immunodeficiency virus type 1 can recombine and initiate a spreading infection in vitro | |
EP2737060B1 (en) | Method for the production of retroviral particles useful for transducing eukaryotic cells | |
WO2013153361A1 (en) | Gene expresssion from mitotically stable episomes | |
AU1333797A (en) | Method for obtaining retroviral vector supernatant having high transduction efficiency | |
US10870865B2 (en) | Particle for the encapsidation of a genome engineering system | |
CN102002514B (zh) | Hsv/φc31杂合性扩增子载体系统及其制备方法 | |
Perron et al. | Human retroviral sequences associated with extracellular particles in autoimmune diseases: epiphenomenon or possible role in aetiopathogenesis? | |
Bacharach et al. | Deletion of a short, untranslated region adjacent to the polypurine tract in Moloney murine leukemia virus leads to formation of aberrant 5′ plus-strand DNA ends in vivo | |
Anderson et al. | Effect of the murine leukemia virus extended packaging signal on the rates and locations of retroviral recombination | |
Delenda et al. | Biosafety issues in lentivector production | |
Neumann et al. | Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV (HIV-1) pseudotype vector | |
CN102851317A (zh) | 用于艾滋病基因治疗的携带多靶点RNAi的慢病毒制备及应用 | |
Lei et al. | Stoichiometric limitations in assembly of active recombinant retrovirus | |
Mathivanan | Lentiviral System for Gene Delivery into Resting T-cells | |
Nickl | Targeted cleavage of the HIV-1 genome in human cells using AAV-delivered CRISPR/Cas9 | |
Yu et al. | Review and future perspectives on the integration characteristics for equine lentivirus in the host genome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING AIKANG RUIHAO BIOLOGICAL TECHNOLOGY LLC Free format text: FORMER OWNER: FUDAN UNIVERSITY Effective date: 20150114 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200433 YANGPU, SHANGHAI TO: 101300 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: 101300, room 2, floor 4, building 5, 218 East Road, Haidian District, Beijing Patentee after: Hao Rui Beijing Kang'ai biological technology limited liability company Address before: 220 Handan Road, Shanghai, No. 200433 Patentee before: Fudan University |
|
C56 | Change in the name or address of the patentee |
Owner name: BEIJING BIOHEALTHCARE BIOTECHNOLOGY CO., LTD. Free format text: FORMER NAME: BEIJING AIKANG RUIHAO BIOLOGICAL TECHNOLOGY LLC |
|
CP03 | Change of name, title or address |
Address after: 101300, Beijing, Haidian District information industry base on the third floor, No. 1, building four, paragraph 417, C Patentee after: The great biotech inc of Beijing Kang Airui Address before: 101300, room 2, floor 4, building 5, 218 East Road, Haidian District, Beijing Patentee before: Hao Rui Beijing Kang'ai biological technology limited liability company |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160322 Address after: 101318, room 3, building 28, No. 201, Yuhua Road, Shunyi District Economic Zone, Beijing Patentee after: Beijing Kang'ai Rui Hao Cell Technology Co. Ltd. Address before: 101300, Beijing, Haidian District information industry base on the third floor, No. 1, building four, paragraph 417, C Patentee before: The great biotech inc of Beijing Kang Airui |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100915 Termination date: 20180515 |